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The Use of Opioids in the Last
Week of Life in an Acute Palliative
Care Unit
Sebastiano Mercadante, MD1,2, Patrizia Ferrera, MD1, and
Alessandra Casuccio, BS3
Abstract
The aim of this survey was to assess the opioid use in the last week of life of cancer patients admitted at an acute palliative care
unit. From a consecutive sample of patients surveyed for a period of one year, patients who died in the unit were selected. Type of
opioid, route of administration, and doses were recorded one week before death (or at admission time if the interval admission-
death was less than one week) (7), and on the day of death (Tend). Seventy-seven patients died in the unit in the period taken
into consideration (12.4%). Oral morphine equivalents were 170 mg/day and 262 mg/day at 7 and Tend, respectively. Patients
were receiving transdermal drugs or intravenous morphine at Tend, with a trend in the use of intravenous morphine at Tend
(p¼0.07). Intravenous morphine was more frequently used in sedated patients at Tend (p¼0.015).No differences in age,
gender, opioid doses, and OEI were found among opioids used. In patients who were sedated doses of opioids were
significantly increased (p¼0.012). In the last week of life intravenous morphine is the preferred modality to deliver opioids in
an acute palliative care unit. Doses increases prevalently observed in sedated patients were performed before starting
sedation with the purpose to treat concomitant distressing symptoms, such as dyspnoea.
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Introduction
Opioid use is of paramount importance to relieve cancer pain,
particularly when death is approaching. Controversies sur-
rounding the risks, the benefits, and ethical foundation for the
use of opioids at the end of life have been discussed extensively
in both the ethical and medical literature. Opioids have become
tainted with the implication that they hasten death, although
studies have found a lack of association between opioid dose
or incremental opioid dose and length of survival in patients
with advanced cancer, close to death.1-3 There is a great varia-
bility among patients with advanced cancer in the experience of
pain of the last days of life.4 Pain and symptoms may become
more severe as death approaches, explaining the use of higher
doses of opioids.
Mean doses of opioid used at the time of death varied widely
between studies, and different pain trajectories have been
described. In some cases, a crescendo of pain has been
reported,4 whereas in other situations, pain remains stable or
tends to diminish in the last days to weeks, as reported in dif-
ferent settings.5-7 However, opioids can be indicated to treat
intractable dyspnoea, generally at higher doses in comparison
with doses required for pain relief, and in a clinical scenario,
it is often difficult to distinguish ‘‘how much’’ is given for one
indication or for another one. Information regarding the use of
opioids in the last week of life in an acute palliative care unit is
lacking. As a part of a secondary analysis of a previous survey,8
we analyzed the pattern of opioid use in the last week of life in
patients with advanced cancer, who died after admission to an
acute palliative care unit.
Patients and Methods
The protocol study was approved by the ethical committee of
the University of Palermo, and informed consent to use the data
was obtained from relatives. From a consecutive sample of
patients with cancer admitted to an acute palliative care unit for
a period of 1 year, patients who died after admission were
included in this survey. Basic information was recorded,
including tumor diagnosis, age, and gender.
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Opioid therapy, including type of opioids, dose, and route of
administration, prescribed 7 days before death (7) and the
same day of death (Tend) were recorded. If survival was less
than a week, data for 7 were recorded on the day of admis-
sion. Number of patients who required sedation before death
was also recorded.
Opioid escalation index (OEI), in milligrams or as percent-
age, was calculated from the initial dose at 7 until Tend,
according to the following formula:
OEI%: [(x  y)/y]/days  100,
where x is the last dose before death and y is the dose at 7,
both expressed as equivalents of oral morphine, and OEI mg
is (x  y)/days.9 Oral morphine equivalents were calculated
according to department policy,10 the conversion ratios used
among opioids and routes of administration being the following:
oral morphine 100 ¼ intravenous morphine 33 ¼ transdermal
(TTS) buprenorphine 1.3 ¼ TTS fentanyl 1 ¼ intravenous fen-
tanyl 1 ¼ oral methadone 20 ¼ intravenous methadone
16 ¼ oral oxycodone 70, transdermal buprenorphine 1.3.
Statistical Analysis
Data were collected and analyzed by the Statistical Package for
the Social Sciences (SPSS) Software 14.0 version (SPSS, Inc,
Chicago, Illinois). Statistical analysis of quantitative data,
including descriptive statistics, was performed for all the items.
Frequency analysis was performed using chi-square test. The
paired samples Student t test was used to compare the differ-
ences in opioid doses at the time intervals. The 1-way analysis
of variance (ANOVA) was used to compare the different para-
metric variables. All P values were 2-sided and P values less
than .05 were considered to indicate statistical significance.
Results
A total of 77 patients died in the unit in the period taken into
consideration (12.4% of 618 admissions recorded in 1 year).
At 7, 58 patients were receiving opioids at a mean oral mor-
phine equivalent dose of 170 mg/d. Doses significantly
increased up to 262 mg/d before death (P ¼ .040; see Table 1).
While only about 15% of patients were still receiving oral
opioids at 7, almost all patients were receiving transdermal
drugs or intravenous morphine at Tend. There was a trend in
the use of intravenous morphine at Tend (P ¼ .07), which was
significant in sedated patients (P ¼ .015). Number of patients
receiving the different opioids are presented in Table 2.
In all, 42 patients required terminal sedation, mainly with
midazolam. About 80% of these patients were receiving
opioids. No differences in age (P ¼ .227), gender (P ¼ .699),
opioid doses at T0 (P ¼ .912), opioid doses at Tend (P ¼
.826) were found between patients who were sedated and
patients who were not sedated. Sedated patients had an admis-
sion time longer than patients who were not sedated (P¼ .005).
Changes in opioid doses were found between T7 and Tend. In
patients who were sedated, doses of opioids were significantly
increased (P ¼ .012), whereas no significant changes were
found in nonsedated patients (P ¼ .274).
Discussion
This survey showed that patients close to death present com-
plex problems requiring different approaches with opioids in
terms of doses and routes of administration, according to clin-
ical individual needs. The findings of this study confirm the
peculiarity of this phase in patients admitted in an acute pain
relief and palliative care unit. As expected, intravenous mor-
phine was most frequently used at time of death, particularly
in patients who required sedation. This route is preferred in our
acute palliative care unit because it warrants a prompt and pre-
dictable effect. Alternatively, transdermal drugs were fre-
quently used, because most patients were unable to swallow.
Opioid doses increased, particularly in patients who were then
sedated, possibly to treat other symptoms, like dyspnoea.
Mean doses of opioids used at the time of death vary widely
between studies, ranging from 59 to 659 mg with an average of
Table 1. Characteristics of Patients and Doses of Opioids Expressed
as Oral Morphine Equivalents
Patients 77
Age (years) 62.5 (95% CI 59-65)
Gender, M/F 48/29
Sedation 42/77
Patients receiving opioids at T7/Tend 58/61
Oral morphine equivalents at T7 (mg) 170 (95% CI 118-222)
Oral morphine equivalents at Tend (mg) 262 (95% CI 130-394)a
OEI% 8.4 (95% CI 3-14)
OEI mg 13.3 (95% CI 3-23)
a T7 versus Tend: P ¼ .040. Opioid escalation index (OEI)% and OEI mg.
Table 2. Number of Patients Receiving Different Opioids and Route
of Administration at T7 and Tend
OS TTS IV IT Total
T7
Oxycodone paracetamol 2 0 0 0 2
Morphine 1 0 19 1 21
Methadone 2 0 4 0 6
Fentanyl 0 10 0 0 10
Oxycodone 6 0 0 0 6
Buprenorphine 0 13 0 0 13
Total 11 23 23 1 58
Tend
Tramadol 0 0 1 0 1
Morphine 1 0 30 1 32
Metadone 0 0 4 0 4
Fentanyl 0 9 0 0 9
Oxycodone 2 0 0 0 2
Buprenorphine 0 14 0 0 14
Total 3 23 34 1 61
Abbreviations: IV, intravenous; IT, intrathecal; OS, oral; TTS, transdermal.
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192 mg of morphine, with doses in North America being the
highest than elsewhere.11 In a recent retrospective analysis of
intravenous morphine patient-controlled analgesia in home
care patients, opioid doses remained stable, in the range of
96 to 115 mg/d, in the last week of life, although the use of such
a technique is questionable in severely ill patients.12 In a hos-
pice setting in United Kingdom, lower doses of opioids were
used in the last week of life. The mean daily opioid dose
increased from 42 to 55.5 mg over the last 7 days of life, with
an increase in the number of patients receiving opioids from
61% at admission up to 89%. Marked increases in opioid doses
were not associated with survival, were more likely to be given
for pain, and were often associated with the use of sedatives. Of
interest, such increases were no more likely to occur in the last
48 hours of life than earlier.3 The proportion of patients
requiring high doses of opioids close to the end is commonly
relatively low. Only 7% to 12% of patients required doses of
more than 300 mg of morphine.2-13
Unfounded concerns about the possible life-shortening
effect of opioids may result in less than optimal symptom man-
agement in end-of-life care.14 Some studies have examined the
relationship between the use of opioid and survival but none of
them reported that opioids had shortened life. In a survey of a
hospice population, the final opioid dose, but not percentage
change in dose, was only one of the several factors associated
with a shorter survival.1 No differences in survival between
patients receiving high doses and those receiving low doses
have been found.13 In a group of patients receiving relatively
high doses of opioids, an increased survival was found in
patients who were on 300 mg/d or more of oral morphine
equivalents.15 In previous studies, no significant differences
in survival were found in patients who received higher doses
of opioids2 and opioid doses were mainly found unchanged
after starting sedation,5,16 mostly lower than 300 mg of oral
morphine equivalents, suggesting that this drug class was admi-
nistered with the purpose of providing analgesia, rather than
sedation.2,17
In this survey, 47 patients increased their opioid doses,
27 patients did not change opioid doses, and in 3 patients,
opioid doses were decreased, although minimally. High doses
were relatively more frequent: 13 patients (16.8%) received
oral morphine equivalents of more than 300 mg, most of them
being sedated patients (12.9%). Moreover, the number of
patients receiving opioids at admission was higher than in pre-
vious hospice experiences.3 Opioid doses significantly
increased in the last week of life, with an OEI% of 8.4. How-
ever, whereas no significant changes in opioid were found from
7 to Tend in nonsedated patients, opioid doses increased sig-
nificantly in the group of patients who were sedated. This could
reflect the selectivity of patients admitted in an acute palliative
care unit and the use of opioids for other purposes, like dys-
pnoea. Treating dyspnoea, in fact, commonly requires higher
doses in patients receiving opioids for their pain. Of interest,
8 patients requiring high doses were already receiving such
doses at 7. In fact, in the primary analysis, these increases
in opioid doses were minimal in the interval between starting
sedation and death, on average 24 hours.16 Agitated delirium,
dyspnoea, and existential distress are the most common prob-
lem requiring sedation,5,18,19 while pain is hardly a unique indi-
cation to sedate or is associated with other manifestations of
suffering. Thus, the increase in opioid doses could be partially
attributed to the large number of patients presenting dyspnoea
in the sedated group of patients, in an attempt to treat dyspnoea
before starting sedation. In this context, in fact, opioids were
not given for sedating purposes, as the level of consciousness
was modulated by midazolam.14 Opioid administration should
be continued once sedation is initiated, as there is no tangible
evidence that patients do not experience pain. Regretfully,
opioids have been found to be administered alone as sedative
agents in general practice.20-22 Concerns were also reported
in other multicenter surveys where a small number of patients
experienced fatal complications related to sedation.19
There are some limitations in the interpretation of the results
of the current study. The need of increase in opioid dose is dif-
ficult to discern in a clinical scenario, when opioids are used for
different indications, for example pain and dyspnoea. Further-
more, these findings cannot be generalized due to the character-
istics of the unit, the selected population, and the level of
monitoring and medicalization described elsewhere.23 How-
ever, the aim of the study was exactly to describe what occurs
in an acute pain relief and palliative care unit, which is
relatively less frequently reported in the literature where data
gathered from hospice and home care settings prevail.
In conclusion, in an acute setting, patients close to death
present complex problems requiring different approaches with
opioids in terms of doses and routes of administration, accord-
ing to different clinical circumstances. Intravenous morphine
was most frequently used at time of death. Alternatively, trans-
dermal drugs were most frequently used, because most patients
were unable to swallow. Opioid doses changed in the last week
of life, with increases more frequently observed in patients who
were subsequently sedated, possibly in an attempt to treat
dyspnoea.
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